BRAF and melanoma: Interestingly, two ongoing clinical studies are currently analyzing the kinetics and effects of BRAF inhibition with vemurafenib (960 mg BID) on the innate and adaptive immune system in patients with unresectable melanoma expressing a BRAFV600 mutation (NCT01942993 and NCT01813214).